FrancophonIA/ELRC3.0 huggingface dataset:
English: Use in children and adolescents aged 6-17 years
Croatian: Primjena u djece i adolescenata u dobi od 6-17 godina
English: The starting dose for all patients was 5 mg rosuvastatin once daily.
Croatian: Početna doza za sve bolesnike bila je 5 mg rosuvastatina jednom dnevno.
English: You should continue with your cholesterol-lowering diet and exercise while you are taking CRESTOR.
Croatian: Trebali biste nastaviti s prehranom za smanjenje kolesterola i s tjelovježbom dok uzimate CRESTOR.
English: The safety and efficacy of use in children younger than 6 years has not been studied.
Croatian: Sigurnost i djelotvornost primjene kod djece mlađe od 6 godina nisu ispitivane.
English: [The wording of the indication for treatment of hypercholesterolaemia should be replaced with the following:]
Croatian: [Tekst indikacije za liječenje hiperkolesterolemije treba zamijeniti sljedećim:]
English: The 40 mg tablet is not suitable for use in paediatric patients.
Croatian: Tablete od 40 mg nisu prikladne za primjenu kod pedijatrijskih bolesnika.
English: • If the patient is under 6 years old: CRESTOR should not be given to children younger than 6 years.
Croatian: • Ako je bolesnik mlađi od 6 godina: CRESTOR se ne smije davati djeci mlađoj od 6 godina.
English: Experience in children with homozygous familial hypercholesterolaemia is limited to a small number of children aged between 8 and 17 years.
Croatian: Iskustvo kod djece s homozigotnom obiteljskom hiperkolesterolemijom ograničeno je na malen broj djece u dobi od 8 do 17 godina.
English: Therefore, Crestor is not recommended for use in children younger than 6 years.
Croatian: Stoga se Crestor ne preporučuje za primjenu kod djece mlađe od 6 godina.
English: CRESTOR 40 mg tablet should not be used by children.
Croatian: CRESTOR tableta od 40 mg se ne smije koristiti kod djece.
English: • If the patient is below 18 years of age: The CRESTOR 40 mg tablet is not suitable for use in children and adolescents below 18 years of age.
Croatian: • Ako je bolesnik mlađi od 18 godina: CRESTOR tableta od 40 mg nije primjerena za liječenje djece i adolescenata mlađih od 18 godina.
English: Titration should be conducted according to the individual response and tolerability in paediatric patients, as recommended by the paediatric treatment recommendations (see Section 4.4).
Croatian: Titraciju treba provoditi sukladno individualnom odgovoru i podnošljivosti kod pedijatrijskih bolesnika, prema smjernicama za liječenje pedijatrijske populacije (vidjeti dio 4.4).
English: The maximum daily dose of CRESTOR is 10 mg for children aged 6 to 9 years and 20 mg for children aged 10 to 17 years.
Croatian: Maksimalna dnevna doza CRESTORA je 10 mg za djecu u dobi od 6 do 9 godina te 20 mg za djecu u dobi od 10 do 17 godina.
English: The European Medicines Agency has waived the obligation to submit the results of studies with rosuvastatin in all subsets of the paediatric population in the treatment of homozygous familial hypercholesterolaemia, primary combined (mixed) dyslipidaemia and in the prevention of cardiovascular events (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove je izuzela obvezu podnošenja rezultata ispitivanja rosuvastatina u svim podskupinama pedijatrijske populacije u liječenju homozigotne obiteljske hiperkolesterolemije i primarne kombinirane (miješane) dislipidemije te prevenciji kardiovaskularnih događaja (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: Safety and efficacy of doses greater than 20 mg have not been studied in this population.
Croatian: Sigurnost i djelotvornost doza većih od 20 mg nisu ispitivane u ovoj populaciji.
English: Safety and efficacy of doses greater than 10 mg have not been studied in this population.
Croatian: Sigurnost i djelotvornost doza većih od 10 mg nisu ispitivane u ovoj populaciji.
English: What CRESTOR is and what it is used for [Existing wording of this section should be replaced with the following:] CRESTOR belongs to a group of medicines called statins.
Croatian: [Postojeći tekst u ovome dijelu treba zamijeniti sljedećim:] CRESTOR pripada skupini lijekova koji se zovu statini.
English: You have been advised to take a statin, because changing your diet and taking more exercise were not enough to correct your cholesterol levels.
Croatian: Statin Vam je propisan zato što promjenom prehrane i tjelovježbom niste mogli dovoljno sniziti razinu kolesterola u krvi.
English: In a clinical trial of children and adolescents receiving rosuvastatin for 52 weeks, CK elevations >10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently compared to observations in clinical trials in adults (see Section 4.8).
Croatian: U kliničkoj studiji na djeci i adolescentima koji su primali rosuvastatin tijekom 52 tjedna, češće su primijećena povećanja CK >10x iznad gornje granice referentne vrijednosti i mišićni simptomi poslije tjelovježbe ili povećane fizičke aktivnosti u usporedbi s nalazima iz kliničkih studija na odraslima (vidjeti dio 4.8).
English: The evaluation of linear growth (height), weight, BMI (body mass index), and secondary characteristics of sexual maturation by Tanner staging in paediatric patients 6 to 17 years of age taking rosuvastatin is limited to a two-year period.
Croatian: Procjena linearnog rasta (visine), težine, BMI (indeksa tjelesne mase) i sekundarnih karakteristika spolnog sazrijevanja prema Tannerovoj ljestvici kod pedijatrijskih bolesnika u dobi 6 do 17 godina, koji uzimaju rosuvastatin je ograničena na razdoblje od dvije godine.
English: At study entry, approximately 30% of the patients were 10-13 years and approximately 17%, 18%, 40%, and 25% were Tanner stage II, III, IV, and V, respectively.
Croatian: Na početku ispitivanja, približno 30% bolesnika je bilo u dobi između 10 i 13 godina i približno 17% ih je bilo u Tanner stadiju II, 18% u Tanner stadiju III, 40% u Tanner stadiju IV i 25% u Tanner stadiju V.
English: Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.
Croatian: Prije početka liječenja rosuvastatinom, djeca i adolescenti trebaju biti podvrgnuti standardnoj dijeti za snižavanje razine kolesterola; ova dijeta se treba nastaviti i tijekom liječenja rosuvastatinom.
English: • You have other factors that increase your risk of having a heart attack, stroke or related health problems.
Croatian: Vaš rizik za nastanak srčanog ili moždanog udara, ili s njima povezanih zdravstvenih problema.
English: Rosuvastatin was also studied in a 2-year open-label, titration-to-goal study in 198 children with heterozygous familial hypercholesterolaemia aged 6 to 17 years (88 male and 110 female, Tanner stage <II-V).
Croatian: Rosuvastatin je ispitivan i u 2-godišnjem otvorenom ispitivanju titracije do ciljnih vrijednosti, u kojem je sudjelovalo 198 djece s heterozigotnom obiteljskom hiperkolesterolemijom u dobi od 6 do 17 godina (88 dječaka i 110 djevojčica, Tanner stadij < II-V).
English: In a double-blind, randomized, multi-centre, placebo-controlled, 12-week study (n=176, 97 male and 79 female) followed by a 40-week (n=173, 96 male and 77 female), open-label, rosuvastatin dosetitration phase, patients 10-17 years of age (Tanner stage II-V, females at least 1 year postmenarche) with heterozygous familial hypercholesterolaemia received rosuvastatin 5, 10 or 20 mg or placebo daily for 12 weeks and then all received rosuvastatin daily for 40 weeks.
Croatian: U dvostruko-slijepom, randomiziranom, multicentričnom, placebom-kontroliranom 12-tjednom kliničkom ispitivanju (n = 176; 97 dječaka i 79 djevojčica) nakon kojeg je slijedila 40-tjedna (n = 173; 96 dječaka i 77 djevojčica), otvorena faza titracije doze rosuvastatina, bolesnici starosti 10-17 godina (Tanner stadij II-V, djevojčice kod kojih je prošlo najmanje godina dana od prve mjesečnice) s heterozigotnom obiteljskom hiperkolesterolemijom uzimali su rosuvastatin 5, 10 ili 20 mg ili placebo svaki dan tijekom 12 tjedana, a nakon toga su svi uzimali rosuvastatin jednom dnevno u trajanju od 40 tjedana.
English: Paediatric population Paediatric use should only be carried out by specialists.
Croatian: Primjenu lijeka kod djece smiju provoditi samo liječnici specijalisti.
English: At the end of the 40-week, open-label, titration to goal, dosing up to a maximum of 20 mg once daily, 70 of 173 patients (40.5%) had achieved the LDL-C goal of less than 2.8 mmol/l.
Croatian: Na kraju 40-tjedne, otvorene titracije do ciljnih vrijednosti, s doziranjem do maksimalno 20 mg jednom dnevno, 70 od 173 bolesnika (40,5%) je postiglo ciljnu vrijednost LDL kolesterola koja je niža od 2,8 mmol/L.
English: LDL-C was reduced 38.3%, 44.6%, and 50.0% by rosuvastatin 5, 10 and 20 mg, respectively, compared to 0.7% for placebo.
Croatian: LDL kolesterol je bio snižen za 38,3% uzimanjem 5 mg rosuvastatina, 44,6% uzimanjem 10 mg rosuvastatina i 50,0% uzimanjem 20 mg rosuvastatina u usporedbi s 0,7% kod placeba.
English: Rosuvastatin 5 mg, 10 mg, and 20 mg also achieved statistically significant mean changes from baseline for the following secondary lipid and lipoprotein variables: HDL-C, TC, non-HDL-C,LDL-C/HDLC, TC/HDL-C, TG/HDL-C, non HDL C/HDL-C, ApoB, ApoB/ApoA-1.
Croatian: Primjenom rosuvastatina u dozi od 5 mg, 10 mg i 20 mg postignute su i statistički značajne srednje promjene u odnosu na početnu vrijednost za sljedeće sekundarne lipidne i lipoproteinske varijable: HDL kolesterol, ukupni kolesterol, ne-HDL kolesterol, omjer LDL i HDL kolesterola, omjer ukupnog i HDL kolesterola, omjer triglicerida i HDL kolesterola, omjer ne-HDL i HDL kolesterola, ApoB, omjer ApoB i ApoA-1.
English: 4.4 Special warnings and precautions for use [Existing information on the paediatric population should be replaced with the following:] Paediatric population
Croatian: 4.4 Posebna upozorenja i mjere opreza pri uporabi [Postojeće informacije o pedijatrijskoj populaciji treba zamijeniti sljedećima:]
English: Homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.
Croatian: Homozigotna obiteljska hiperkolesterolemija, kao dodatak dijeti i drugim postupcima snižavanja lipida (npr. afereza LDL- kolesterola) ili u slučajevima kad ti postupci nisu primjereni.
English: Patients aged 6 to 9 years (n=64) could titrate to a maximum dose of 10 mg once daily and patients aged 10 to 17 years (n=134) to a maximum dose of 20 mg once daily.
Croatian: Kod bolesnika u dobi od 6 do 9 godina (n=64) doza se mogla titrirati do maksimalne doze od 10 mg jednom dnevno, a kod bolesnika u dobi od 10 do 17 godina (n=134) do maksimalne doze od 20 mg jednom dnevno.
English: After 24 months of treatment with rosuvastatin, the LS mean percent reduction from the baseline value in LDL-C was -43% (Baseline: 236 mg/dL, Month 24: 133 mg/dL).
Croatian: Nakon 24 mjeseca liječenja rosuvastatinom, srednje postotno smanjenje LDL kolesterola od početne vrijednosti izračunato metodom najmanjih kvadrata iznosilo je -43% (početna vrijednost: 236 mg/dl, 24. mjesec: 133 mg/dl).
English: Children and adolescents 6 to 17 years of age (Tanner Stage <II-V) In children and adolescents with heterozygous familial hypercholesterolaemia the usual start dose is 5 mg daily.
Croatian: Djeca i adolescenti u dobi od 6 do 17 godina (Tanner stadij < II-V) Uobičajena početna doza za djecu i adolescente s heterozigotnom obiteljskom hiperkolesterolemijom je 5 mg dnevno.
English: Adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.
Croatian: Primarna hiperkolesterolemija (tip IIa uključujući heterozigotnu obiteljsku hiperkolesterolemiju) ili miješana dislipidemija (tip IIb) kod odraslih, adolescenata i djece u dobi od 6 ili više godina, kao dodatak dijeti, kad odgovor na dijetu i druge nefarmakološke mjere (primjerice vježbanje, smanjenje težine) nije zadovoljavajuć
English: How to take CRESTOR [Existing information on the paediatric population should be replaced with the following:]
Croatian: 3. Kako uzimati CRESTOR [Postojeće informacije o pedijatrijskoj populaciji treba zamijeniti sljedećima:]
English: AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE PACKAGE LEAFLET FOR CRESTOR AND ASSOCIATED NAMES
Croatian: IZMJENE KOJE TREBA UNIJETI U ODGOVARAJUĆE DIJELOVE UPUTE O LIJEKU ZA CRESTOR I PRIDRUŽENA IMENA
English: After two years of study treatment, no effect on growth, weight, BMI or sexual maturation was detected (see Section 5.1).
Croatian: Nakon dvije godine liječenja tijekom ispitivanja nisu primijećeni nikakvi učinci na rast, težinu, BMI ili spolno sazrijevanje (vidjeti dio 5.1).
English: For each age group, the LS mean percent reductions from baseline values in LDL-C were -43% (Baseline: 234 mg/dL, Month 24: 124 mg/dL), -45% (Baseline: 234 mg/dL, 124 mg/dL ), and -35% (Baseline: 241 mg/dL, Month 24: 153 mg/dL) in the 6 to <10, 10 to <14, and 14 to <18 age groups, respectively.
Croatian: Srednje postotno smanjenje LDL kolesterola od početne vrijednosti izračunato metodom najmanjih kvadrata po dobnim skupinama iznosilo je: -43% u dobnoj skupini od 6 do <10 godina (početna vrijednost: 234 mg/dl, 24. mjesec: 124 mg/dl), -45% u dobnoj skupini od 10 do <14 godina (početna vrijednost: 234 mg/dl, 24. mjesec: 124 mg/dl ) te -35% u dobnoj skupini od 14 do <18 godina (početna vrijednost: 241 mg/dl, 24. mjesec: 153 mg/dl).
English: • In children 6 to 9 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-10 mg orally once daily.
Croatian: • Kod djece u dobi od 6 do 9 godina s heterozigotnom obiteljskom hiperkolesterolemijom uobičajena doza kreće se u rasponu od 5-10 mg peroralno jednom dnevno.
English: This Summary of Product Characteristics and package leaflet is the outcome of the referral procedure and valid at the time of the Commission Decision.
Croatian: Ovaj Sažetak opisa svojstava lijeka i Uputa o lijeku ishod su arbitražnog postupka.
English: • In children 10 to 17 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-20 mg orally once daily.
Croatian: • Kod djece u dobi od 10 do 17 godina s heterozigotnom obiteljskom hiperkolesterolemijom uobičajena doza kreće se u rasponu od 5-20 mg peroralno jednom dnevno.
English: After 52 weeks of study treatment, no effect on growth, weight, BMI or sexual maturation was detected (see Section 4.4).
Croatian: Nakon 52 tjedna liječenja tijekom ispitivanja, nisu otkriveni učinci na rast, tjelesnu težinu, BMI ili spolno sazrijevanje (vidjeti dio 4.4).
English: 5.2 Pharmacokinetic properties [Existing information on the paediatric population should be replaced with the following:] Paediatric population: Two pharmacokinetic studies with rosuvastatin (given as tablets) in paediatric patients with heterozygous familial hypercholesterolaemia 10-17 or 6-17 years of age (total of 214
Croatian: Pedijatrijska populacija: Dva farmakokinetička ispitivanja rosuvastatina (primijenjenog u obliku tableta) kod pedijatrijskih bolesnika s heterozigotnom obiteljskom hiperkolesterolemijom u dobi od 10-17 ili 6-17 godina (ukupno 214 bolesnika) pokazala su da je izloženost lijeku kod pedijatrijskih bolesnika usporediva ili manja od izloženosti kod odraslih bolesnika.
English: [Existing information on the paediatric population should be replaced with the following:] Children and adolescents
Croatian: Što morate znati prije nego počnete uzimati CRESTOR [Postojeće informacije o pedijatrijskoj populaciji treba zamijeniti sljedećima:] Djeca i adolescenti
English: No effect on growth, weight, BMI or sexual maturation was detected after 24 months of treatment (see Section 4.4).
Croatian: Nakon 24 mjeseca liječenja nisu primijećeni učinci na rast, tjelesnu težinu, BMI ni spolno sazrijevanje (vidjeti dio 4.4).
English: What you need to know before you take CRESTOR
Croatian: Što je CRESTOR i za što se koristi
English: Amendments to the Summary of Product Characteristics and Package Leaflet
Croatian: Izmjene Sažetka opisa svojstava lijeka i Upute o lijeku koje je predstavila Europska agencija za lijekove
English: The recommended dose is 200 mg once a day for 6 days.
Croatian: Preporučena doza iznosi 200 mg jednom na dan tijekom 6 dana.
English: 85.5% of patients treated with Sivextro in the first study and 88.0% in the second study were cured, compared with 86.0% and 87.7% respectively of patients treated with linezolid.
Croatian: Izlječeno je 85,5% bolesnika liječenih lijekom Sivextro u prvom ispitivanju i 88,0% u drugom ispitivanju, u usporedbi s 86,0% odnosno 87,7% bolesnika liječenih linezolidom.
English: It works by preventing certain bacteria from making proteins, thereby stopping their growth.
Croatian: Djeluje sprječavajući bakterije da proizvode određene proteine, te na taj način sprječava njihov rast.
English: Although the infections in the studies were not severe, the CHMP considered that the results also apply to severe infections.
Croatian: Iako infekcije u ispitivanjima nisu bile ozbiljne, CHMP je zaključio da se rezultati primjenjuju također na ozbiljne infekcije.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Sivextro on 23 March 2015.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Sivextro na snazi u Europskoj uniji od 23. ožujka 2015.
English: In both studies, the main measure of effectiveness was the number of patients whose infection was cured after treatment.
Croatian: U svim ispitivanjima glavna mjera djelotvornosti bio je broj bolesnika čije su infekcije izliječene nakon terapije.
English: Patients who are started on the infusion may be switched to the tablets when appropriate.
Croatian: Bolesnici koji su započeli infuziju mogu prijeći na tablete ako je to primjereno.
English: Other information about Sivextro
Croatian: Ostale informacije o lijeku Sivextro
English: It is not intended to provide practical advice on how to use Sivextro.
Croatian: Svrha sažetka nije davati praktične savjete o načinu korištenja lijeka Sivextro.
English: What is Sivextro and what is it used for?
Croatian: Što je Sivextro i za što se koristi?
English: What measures are being taken to ensure the safe and effective use of Sivextro?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Sivextro?
English: This is a summary of the European public assessment report (EPAR) for Sivextro.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Sivextro.
English: Before using Sivextro, doctors should consider official guidance on the appropriate use of antibiotics.
Croatian: Prije primjene Sivextro liječnici trebaju proučiti službene smjernice o odgovarajućoj primjeni antibiotika.
English: In both studies patients received 6 days of treatment with Sivextro which was compared with a 10-day treatment of linezolid.
Croatian: U oba ispitivanja, bolesnici su primali terapiju lijekom Sivextro tijekom 6 dana što je uspoređeno s desetodnevnom terapijom linezolidom.
English: Why is Sivextro approved?
Croatian: Zašto je Sivextro odobren?
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Sivextro's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka Sivextro nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
English: Sivextro was at least as effective as linezolid at curing the infection.
Croatian: Lijek Sivextro bio je barem jednako djelotvoran kao linezolid u liječenju infekcije.
English: A risk management plan has been developed to ensure that Sivextro is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Sivextro.
English: What are the risks associated with Sivextro?
Croatian: Koji su rizici povezani s lijekom Sivextro?
English: In light of the need for new antibiotics targeting multi-resistant bacteria, especially those available as an oral (given by mouth) formulation, the CHMP concluded that Sivextro could be a valuable alternative treatment option for bacterial infections of the skin and of skin structures.
Croatian: U svjetlu potrebe za novim antibioticima za liječenje bakterija otpornih na više lijekova, posebice na one dostupne kao peroralne formulacije (primjena kroz usta), CHMP je zaključio da Sivextro može biti vrijedna alternativna terapijska opcija za bakterijske infekcije kože i kožnih struktura.
English: Sivextro's safety profile is comparable to that of linezolid and was considered acceptable.
Croatian: Sigurnosni profil lijeka Sivextro usporediv je s profilom linezolida i smatran je prihvatljivim.
English: It contains the active substance tedizolid.
Croatian: Sadrži djelatnu tvar tedizolid.
English: The active substance in Sivextro, tedizolid, is a type of antibiotic called an oxazolidinone.
Croatian: Djelatna tvar lijeka Sivextro, tedizolid, tip je antibiotika naziva oksazolidinon.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Sivextro, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi za lijek Sivextro nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: Sivextro was compared with linezolid (another oxazolidinone) in two main studies involving a total of 1,333 patients with acute bacterial infections of the skin and of skin structures, such as cellulitis, skin abscesses and wound infections.
Croatian: Sivextro je uspoređen s linezolidom (drugim oksazolidinom) u dva glavna ispitivanja koja su obuhvatila ukupno 1.333 bolesnika s akutnim bakterijskim infekcijama kože i kožnih struktura, poput celulitisa, apcesa kože i infekcija rana.
English: The most common side effects with Sivextro (which may affect between 2 and 7 people in 100) are nausea (feeling sick), headache, diarrhoea and vomiting.
Croatian: Najčešće nuspojave lijeka Sivextro (uočene kod između 2 i 7 na 100 bolesnika) su mučnina (osjećaj slabosti), glavobolja, proljev i povraćanje.
English: Sivextro is available as a powder to be made up into a solution for infusion (drip) into a vein and as tablets (200 mg).
Croatian: Sivextro je dostupan kao prašak za pripravak otopine za infuziju (drip) u venu i kao tablete (200 mg).
English: Sivextro can only be obtained with a prescription.
Croatian: Sivextro se izdaje samo na liječnički recept.
English: Sivextro is an antibiotic used in adults to treat acute (short-term) bacterial infections of the skin and of skin structures (tissue below the skin) such as cellulitis (inflammation of the deep skin tissue), skin abscesses and wound infections.
Croatian: Sivextro je antibiotik koji se koristi u odraslih osoba za liječenje akutnih (kratkotrajnih) bakterijskih infekcija kože i struktura kože (tkiva ispod kože) poput celulitisa (upale dubokog kožnog tkiva), kožnih apscesa i infekcija rana.
English: Sivextro has been shown to work against bacteria (such as methicillin resistant Staphylococcus aureus (MRSA)) for which standard antibiotics do not work.
Croatian: Dokazano je da Sivextro djeluje protiv bakterija (poput bakterije Staphylococcus aureus otporne na metilicin (MRSA))